

Results in focus: Majedie Investments

Majedie Investments (MAJE) released its interim results for the half year to 31 March 2020 this morning, including a major overhaul of its valuation methodology for funds business Majedie Asset Management...

Kepler Trust Intelligence

LAST UPDATE 27 MAY 2020

Majedie Investments (MAJE) released its interim results for the half year to 31 March 2020 this morning, reporting a fall in NAV over the period of 22.4% and a share price fall of 30.2% over the same period. Over the six months the FTSE All-Share index fell by 22.0% and the MSCI All Country World Index fell by 14.9% in sterling terms.

The board also announced an interim dividend of 4.4p, in line with the company's 2019 interim dividend, to be paid to shareholders on the register as of the 5 June 2020.

MAJE invests in funds managed by Majedie Asset Management (MAM), alongside holding a 17.2% stake in the asset manager itself. The latter investment has seen an overhaul of its valuation methodology in these results, with the board applying a new formula which it suggests gives a more relevant valuation than the previous methodology, which focused on longer-term historic earnings. As a result, the valuation of the trust's stake in MAM has fallen from £37.8m at 31 December 2019 to £30.6m at 31 March 2020. A full breakdown of this methodology can be seen below.

On the whole, the performance of several of the underlying funds detracted from overall performance, including the trust's UK and US allocations. However, in December 2019 MAJE did invest in a newly-launched MAM fund, the International Equity Fund, which outperformed its benchmark by over 8% over the period from launch to 31 March 2020. The Majedie Global Equity Fund outperformed by 1.4% over the interim results period.

[Click here to read the full results](#)

[Click here to visit MAJE's website](#)

[Click here to read our full research on the trust](#)

Kepler view

With its asset allocation skewed marginally towards the UK, the board noted that the latter stages of 2019 and beginning of 2020 looked promising for the trust. Brexit uncertainty had subsided in the UK, with a new, stable government prompting a surge in the local market.

However, the latter two months of the reporting period were marred on a global basis by the impact of the COVID-19 pandemic. With economies – including the UK's – locking down, all previous market assumptions and outlooks stalled, with the impact still being felt across the asset management industry. While the full impact of the pandemic on the trust will not be seen until next quarter's results, it is fair to say that it has scuppered the long-anticipated resurgence in UK value stocks, which would have been positive for the trust.

Of particular interest for investors is the revised valuation methodology for MAM. The trust's 17.2% stake in the business represents 22.2% of the trust's own assets. In the past, the valuation has been based on historic three year average earnings, combined with a single digit multiple of AuM, after deducting surplus cash over and above the firm's minimum regulatory capital.

The impact of this methodology was that the asset manager's valuation had been especially conservative in rising markets and that the board had felt it necessary to manually adjust it when, for example, the asset management industry as a whole experienced increased downward pressure on fees.

The board's new valuation methodology should offer a more dynamic basis, more representative of MAM's recent condition, as well as removing the necessity for the directors to manually adjust the valuation. In particular, it incorporates the impact of potential industry-wide pressures through the application of a peer group average multiple and reduces the role of volatile performance fees in the valuation by applying a specific discount to these. It also routinely incorporates the company's private status. The fact that a new valuation will be published quarterly means that visibility and disclosure are also improved.



This new methodology has resulted in a fall in the MAM stake's valuation, despite the asset manager seeing net inflows in the most recent quarter, particularly through the appointment to manage Edinburgh Investment Trust PLC.

NEW VALUATION METHODOLOGY FOR MAJEDIE ASSET MANAGEMENT

"The revised basis for valuation annualises the most recent quarterly earnings of MAM, applies a median of a peer group price earnings multiple with an unlisted liquidity discount of 20% (although the Directors may adjust the discount depending on market conditions). Performance fee earnings multiples are further discounted by 50%. Surplus net assets are then added, having deducted 200% of Regulatory Capital.

It is intended that the valuation is updated each quarter and will be announced to the market. The Board believes the new valuation methodology will enhance the disclosure and transparency of the Company's investment in MAM for investors."

About MAJE

Majedie Investments (MAM) aims to maximise total shareholder return while increasing dividends by more than the rate of inflation over the long term.

The portfolio is divided into seven funds, all of which are managed by the well-respected boutique fund managers at Majedie Asset Management. MAM was launched in 2002 using finance provided by the investment trust and was led by a team that previously worked at Mercury Asset Management and Merrill Lynch. The strategy was to manage UK equities on behalf of institutional clients, but this has since been broadened to include global equities and an absolute return strategy, and clients now include wealth managers and endowments alongside institutions. The trust has a 17.2% stake in the privately-owned asset management company itself.

Alongside capital growth, dividend growth is an important part of the trust's investment proposition. The board re-set the dividend in 2014 and, since then, shareholders have seen compound progression in excess of 10% pa. The trust is currently yielding 4.6%.

[Click here to read our full research on the trust](#)

This report has been issued by Kepler Partners LLP. **The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.**

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject

to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.